Shenzhen Hepalink Pharmaceutical Group , Ltd. Return on Equity

Shenzhen Hepalink Pharmaceutical Group , Ltd. (SHEZF) currently reports a ROE of 1.7%. That is below the sector sector average of 11.64%. Use the charts on this page to explore Shenzhen Hepalink Pharmaceutical Group , Ltd.'s ROE history and peer comparisons.

Shenzhen Hepalink Pharmaceutical Group , Ltd.'s ROE of 1.7% is lower than the its sector sector average of 11.64%. That is roughly 85.4% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Shenzhen Hepalink Pharmaceutical Group , Ltd.'s current 1.7% should be judged against industry norms (sector average: 11.64%) and against SHEZF's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 1.7%, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is 11.64%. From there, open related valuation or income-statement pages for Shenzhen Hepalink Pharmaceutical Group , Ltd., and consider following SHEZF for alerts when major investors trade the stock.